TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 1 | 0 | 2 | -5 | 6 | -26 | 0 | -6 |
| P | %wins | 100 | 100 | 0 | 100 | 0 | 60 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12/23/20 09:06 | 12/21/20 | SCYX | Scynexis Inc | Health | Drug | Pharmaceutical Preparations | Gilman Steven C | NJ | D | P.d | 25 | 6.25 | 0 | 4 | New | 4 | D | ||||||||||||||||
11/22/19 06:20 | 11/20/19 | AKBA | Akebia Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Gilman Steven C | MA | D | P | 20 | 3.43 | 0 | 6 | 24 | 30 | D | |||||||||||||||
7/26/17 16:42 | 7/25/17 | CFRX | Contrafect Corp | DE | Health | Drug | Pharmaceutical Preparations | Gilman Steven C | MA | DO | CEO | P.d | 1 | 1.24 | 0 | 1 | 4 | 21 | D | ||||||||||||||
7/27/16 17:18 | 7/27/16 | CFRX | Contrafect Corp | DE | Health | Drug | Pharmaceutical Preparations | Gilman Steven C | NY | DO | CEO | P.d | 50 | 2.48 | 0 | 20 | New | 20 | D | -55 | -34 | -40 | -23 | -19 | -11 | -22 | 0 | 2 | -5 | 6 | -26 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |